Inclusion Criteria:

- Histologically or cytologically documented unresectable stage III NSCLC.

- Documented stable disease or objective response, according to RECIST after primary
chemo-radiotherapy (either sequential or concomitant) for unresectable stage III
disease, within four weeks (28 days) prior to randomization.

- Receipt of concomitant or sequential chemo-radiotherapy, consisting of a minimum of
two cycles of platinum-based chemotherapy and a minimum radiation dose of ≥ 50 Gy.
Subjects must have completed the primary thoracic chemo-radiotherapy at least four
weeks (28 days) and no later than 12 weeks (84 days) prior to randomization. Subjects
who received prophylactic brain irradiation as part of primary chemo-radiotherapy are
eligible.

- Geographically accessible for ongoing follow-up, and committed to comply with the
designated visits

- An Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1

- A platelet count ≥ the lower limit of normal for the site or ≥ 100 x 10⁹/L (whichever
is greater); WBC ≥ 2.5 x 10⁹/L and hemoglobin ≥ 90 g/L

- ≥18 years of age (or minimum age of legal consent consistent with local regulations,
if minimum is > 18 years of age)

Exclusion Criteria:

Pre-Therapies*:

- Lung-cancer-specific therapy (including surgery) other than primary
chemoradiotherapy.

- Immunotherapy (e.g., interferons, tumor necrosis factor [TNF], interleukins, or
biological response modifiers [granulocyte macrophage colony stimulating factor
{GMCSF}, granulocyte colony stimulating factor {G-CSF}, macrophage-colony stimulating
factor {M-CSF}], monoclonal antibodies) within four weeks (28 days) prior to
randomization.

- Investigational systemic drugs (including off-label use of approved products) within
four weeks (28 days) prior to randomization.

Disease Status:

- Metastatic disease

- Malignant pleural effusion at initial diagnosis and/or at trial entry

- Past or current history of neoplasm other than lung carcinoma, except for curatively
treated non-melanoma skin cancer, in situ carcinoma of the cervix, or other cancer
curatively treated and with no evidence of disease for at least 5 years

- Autoimmune disease that in the opinion of the investigator could compromise the
safety of the subject in this trial

- A recognized immunodeficiency disease including cellular immunodeficiencies,
hypogammaglobulinemia or dysgammaglobulinemia; subjects who have hereditary or
congenital immunodeficiencies

- Any preexisting medical condition requiring chronic steroid or immunosuppressive
therapy (steroids for the treatment of radiation pneumonitis are allowed)

- Known active Hepatitis B infection and/or Hepatitis C infection

- Signs and symptoms suggestive of transmissible spongiform encephalopathy, or of
family members who suffer(ed) from such

Physiological Functions:

- Clinically significant hepatic dysfunction

- Clinically significant renal dysfunction

- Clinically significant cardiac disease

- Splenectomy

- Infectious process that in the opinion of the investigator could compromise the
subject's ability to mount an immune response

Standard Safety:

- Pregnant or breastfeeding women, women of childbearing potential, unless using
effective contraception as determined by the investigator.

- Known drug abuse or alcohol abuse

- Participation in another clinical trial (excluding purely observational studies)
within the past 28 days

- Requires concurrent treatment with a non-permitted drug

- Known hypersensitivity to any of the trial treatment ingredients

- Legal incapacity or limited legal capacity